Agenus (NASDAQ:AGEN) Upgraded at Wall Street Zen

Agenus (NASDAQ:AGEN) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Monday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Agenus presently has a consensus rating of “Hold” and an average target price of $14.50.

Agenus Stock Performance

AGEN opened at $3.33 on Monday. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The business’s fifty day simple moving average is $3.20 and its 200-day simple moving average is $3.68. The company has a market capitalization of $127.87 million, a price-to-earnings ratio of -7.24 and a beta of 1.60.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $1.83. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.The company had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million. On average, equities research analysts predict that Agenus will post -12.55 EPS for the current year.

Institutional Investors Weigh In On Agenus

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. EP Wealth Advisors LLC purchased a new stake in shares of Agenus in the 4th quarter valued at $31,000. R Squared Ltd purchased a new position in shares of Agenus in the fourth quarter valued at approximately $41,000. Redwood Family Wealth LLC purchased a new position in shares of Agenus in the fourth quarter valued at approximately $44,000. Traynor Capital Management Inc. acquired a new position in shares of Agenus in the third quarter valued at approximately $50,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Agenus in the fourth quarter valued at approximately $54,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Agenus

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Zacks upgraded AGEN to a Zacks Rank #1 (Strong Buy), signaling increased analyst optimism that may attract buyer interest and momentum traders. All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
• Positive Sentiment: Zacks flagged rising earnings estimate revisions as a reason AGEN could move higher — reinforcing the upgrade and suggesting analyst models are shifting toward better near‑term results. Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
• Positive Sentiment: HC Wainwright materially raised several near‑term EPS forecasts (notably Q1 and full‑year FY2026), lifting quarter and FY2026 estimates — a catalyst that can re‑rate the stock if investors believe earnings will improve meaningfully. (Research note summaries)
• Positive Sentiment: Clinical progress: Agenus announced first patient enrolled in the global Phase III BATTMAN trial (BOT+BAL) for MSS/pMMR metastatic colorectal cancer — Phase III starts and patient accrual milestones are commonly positive near‑term catalysts. Agenus enrols first patient in BATTMAN Phase III trial
• Positive Sentiment: Scientific visibility: Data from a Phase II investigator‑initiated study of BOT+BAL with agenT‑797 will be presented at AACR 2026 — upcoming conference exposure can boost investor confidence ahead of or after poster/oral presentation. Agenus Announces Data from Phase II Study … to be Presented at AACR 2026
• Neutral Sentiment: Zacks published broader pieces framing AGEN as a momentum/value/growth idea and compared sector performance — useful for traders but less likely to move the stock materially on its own. Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
• Negative Sentiment: HC Wainwright trimmed some longer‑range estimates (FY2029 and FY2030) even as it lifted near‑term numbers — a reminder that longer‑term profitability remains uncertain and could limit sustained multiple expansion if future guidance weakens. (Research note summaries)

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.